May 22, 2003 |
A U.S. judge ruled that the 1997 agreement between Barr Laboratories Inc. and Bayer to end a patent suit over the anthrax treatment Cipro wasn't anti-competitive, according to Barr. U.S. District Judge David G. Trager in Brooklyn, N.Y., rejected arguments that the settlement violated antitrust laws. The ruling narrows the scope of some 38 antitrust lawsuits filed by consumers and wholesalers against Pomona, N.Y.-based Barr and Leverkusen, Germany-based Bayer.
June 30, 2001 |
Barr Laboratories Inc. said it will acquire Duramed Pharmaceuticals Inc. in a stock swap valued at about $589 million, adding to its line of oral contraceptives and hormone products for women. Barr said it would exchange one of its shares for 3.9032 shares of Duramed. Cincinnati-based Duramed rose 99 cents to $17.89 on Nasdaq, while Barr fell $2.24 to $69.20 on the Big Board.
October 5, 2001 |
Barr Laboratories Inc. said it will earn at least 21% more in its fiscal first quarter than previously thought, as health insurers switch U.S. patients to its generic version of the antidepressant Prozac. Barr's forecast followed a profit warning a day earlier by Indianapolis-based Eli Lilly & Co., which has seen its antidepressant market share fall by more than 80% since it lost patent protection in August. Pomona, N.Y.-based Barr said it would earn $1.75 to $1.
August 15, 2002 |
Drug maker Barr Laboratories Inc. said profit more than doubled in its fiscal fourth quarter, boosted by strong sales of oral contraceptives and generic versions of medicines that recently lost patent protection. Net income climbed to $44.9 million, or 98 cents a share, well above the 85 cents analysts expected, from $19.7 million, or 44 cents, a year earlier. Revenue jumped 27% to $209.4 million.
December 19, 2001 |
Barr Laboratories Inc. said all 50 states, led by Texas, ended an inquiry into whether a 1997 agreement between Barr and Bayer unlawfully delayed generic versions of the antibiotic Cipro. The Texas attorney general's office, acting on behalf of the other 49 states and Puerto Rico, was looking into Barr's agreement to withdraw its patent challenge over Cipro and sign a supply contract with Bayer.
July 10, 2003 |
Barr Laboratories Inc. said it is voluntarily recalling three lots of its Nortrel 7/7/7 28-day oral contraceptive because they might have been improperly packaged, perhaps increasing the risk of pregnancy. The Woodcliff Lake, N.J.-based company said the recall affects lots 290122001, 290122002 and 290122003, involving about 470,000 packages. It said it is implementing the recall because two consumers reported the color-coded tablets were in the wrong sequence.